S
ymptomatic, severe aortic stenosis (AS) is a lethal disease for which aortic valve replacement (AVR) is the only treatment that has been shown to improve survival and quality of life. 1 Indeed, failure to undertake AVR once symptoms develop is associated with a 30% risk of death within 1 year. 2 As with all interventions, the short-and long-term benefits of AVR must be balanced against the risks inherent to the procedure and the presence of a prosthetic valve. In many patients with AS, a risk/benefit analysis is a straightforward exercise, though it can be particularly challenging in patients of advanced age with a higher burden of comorbid medical illnesses and reduced life expectancy. Shared decision-making is a complex process that must consider patient preferences and values, the sometimes divergent views of family members, and the collective judgment of the multidisciplinary heart valve team (MDT). The dynamics of this process have been altered greatly by the transformative emergence of transcatheter AVR (TAVR) as a treatment option for increasing numbers of patients with severe AS. It is now well established that TAVR is superior to medical therapy for inoperable or prohibitive surgical risk patients and noninferior to surgical AVR (SAVR) for both high-and intermediatesurgical risk patients. 1 The results of randomized trials of TAVR versus SAVR in lowsurgical risk patients are eagerly anticipated (NCT02675114, NCT02701283). 3, 4 A trial of TAVR versus active surveillance in asymptomatic patients with severe AS is also underway (NCT03042104).
5 Accordingly, the context in which AVR is performed, and the outcomes that can be reasonably expected, will continue to evolve as younger patients with fewer comorbidities are considered candidates for intervention.
On the other hand, despite the extraordinary successes seen with TAVR, a significant proportion of patients at prohibitive or high surgical risk either die or fail to achieve improved health status by 1 year. 6 Identification of these patients can be challenging, as can be the recalibration of patient and family expectations when the MDT has reached a consensus that TAVR should not be offered. Exercising responsible decision-making and appropriate stewardship of economic resources is a fundamental responsibility of the MDT, yet one that can often lead to controversy. To objectify this process and help guide decision-making, it has been proposed that several factors be considered by the MDT, including clinical and geriatric risk stratification scores, the anticipated clinical benefit based on the cumulative experience with TAVR in comparable patients (Transcatheter Valve Therapy Registry), 7 as well as patient goals and preferences. 8 Geriatric risk assessment is an area that has seen a great deal of progress in recent years, particularly as it pertains to AS. Although traditional models of risk assessment in clinical trials have hinged on the Society of Thoracic Surgeons Predicted Risk of Mortality, there is strong evidence that assessment of frailty is useful to predict outcomes in these patients as well. 9, 10 In an effort to improve geriatric risk stratification, Goldfarb et al 11 present in this issue of Circulation a prospective evaluation of the impact of nutritional status and physical frailty on the outcomes of an international cohort of 1158 patients age ≥70 years (mean age, 81 years) with severe AS undergoing either TAVR or SAVR. To assess malnutrition, the authors used the Mini-Nutritional Assessment-Short Form, a practical, relatively simple, and well-validated model that assigns a numeric score across 6 domains related to food intake, weight loss, body mass index, mobility, neuropsychological impairment, and disease acuity. Patients were characterized according to previously validated cut points as (1) normal nutritional status, (2) at-risk of malnutrition, and (3) malnourished. Patients were also independently assessed for physical frailty with the Short Physical Performance Battery and Fried scale. Approximately 40% of patients were either malnourished or at risk of malnutrition. Patients who were malnourished were more likely to be older, be female, have a higher Society of Thoracic Surgeons Predicted Risk of Mortality score, and have a higher burden of other clinical comorbidities (stroke, lung disease, anemia, chronic kidney disease, and lower ejection fraction). Albumin, which has been included in other geriatric risk assessments, 9, 12 was also found to be lower in the malnourished group.
The majority (62%) of patients underwent TAVR. Notably, the odds ratio for 1-year mortality in the multivariable logistic regression model was significantly higher for TAVR than SAVR, possibly related to patient selection. There was a stepwise and graded association between nutritional status and outcomes for the entire cohort, as well as for the TAVR and SAVR subgroups. One-year all-cause mortality was highest in the malnourished group (28%), intermediate in the at-risk group (16%), and lowest in the normal nutrition group (10%). Malnourished patients had longer intensive care unit stays and were less likely to be discharged directly home. The associations between nutritional status and 30-day safety events, as well as 1-year mortality, remained after adjustment for Society of Thoracic Surgeons Predicted Risk of Mortality, physical frailty, and procedure type. The odds ratio for 1-year mortality rate was highest (3.21; 95% CI, 1.66-6.21) among patients who were both malnourished and frail.
Nutritional status is an important consideration in the assessment of patients for conventional cardiac surgery and has been shown to predict postoperative complications. 13 Data regarding the frequency and impact of malnutrition among high-risk cohorts have been lacking, despite their potential utility to help guide patient selection for intervention. The association demonstrated herein between poor nutritional status and clinical outcomes after AVR has significant implications, not only for risk assessment but also for preprocedural patient optimization. The Mini-Nutritional Assessment-Short Form is a well-validated and simple assessment tool that can easily be administered in an office setting. Whereas In evaluating patients in the heart valve clinic, several domains must be considered. The clinical assessment is key in confirming the diagnosis, assessing for the presence of other comorbidities, and anatomic assessment for procedural risk. Risk assessment by the Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) calculator should be paired with objective assessments of quality of life (QOL), frailty, and nutrition as well as the goals and preferences of the patient and family. Using this integrative approach, the optimal treatment strategy can be tailored. In patients who are deemed to be high or prohibitive risk by the MDT, specific attention should be given toward frailty and nutrition. In those patients who are not frail or malnourished, consideration of transcatheter aortic valve replacement (TAVR) is reasonable. In those who are frail or malnourished, targeted therapies aimed at reducing frailty and malnutrition should be explored and implemented if possible. Interval reassessment by the MDT should then follow and, if objective improvements in frailty and nutrition have been met, it is reasonable to reconsider TAVR. If, despite these interventions, these patients remain frail or malnourished, medical therapy with concomitant end-of-life (EOL) planning is recommended. KCCQ indicates Kansas City Cardiomyopathy Questionnaire. a previous study related nutritional status to outcomes after TAVR, 12 the additive effect of using the Mini-Nutritional Assessment-Short Form in combination with a frailty assessment tool is both novel and practical. Replacing the currently utilized standard 5-meter walk test (Transcatheter Valve Therapy Registry) 14 with a more rigorous assessment of frailty (Fried scale, Short Physical Performance Battery) should be considered. It would also be of interest to explore whether there is additive prognostic value in combining the Mini-Nutritional Assessment-Short Form with the Essential Frailty Toolset, 9 given the overlap between these 2 instruments. Regardless, identification of both malnutrition and frailty should alert clinicians to heightened risk and the even higher potential for a poor outcome.
It is equally important to recognize that the authors have identified a potential treatment strategy worthy of immediate study-that is, whether targeted preprocedural nutritional interventions might improve outcomes after AVR in vulnerable patients. Although several interventions that prevent or reverse frailty have been identified, all require engagement in physical training, which in turn can be challenging for patients with symptomatic severe AS. 15 Improving nutritional status, on the other hand, may be more easily accomplished and could emerge as a practical means to help optimize short-and intermediate-term outcomes.
The findings presented by Goldfarb et al 11 support the clinical intuition that nutritional status matters. They also provide an obvious wake-up call to the MDT that objective assessment of this vital attribute be routinely incorporated in at-risk patients (see Figure) . Previously overlooked but simple observations of this nature can often have a significant impact on clinical practice. It is important to realize, however, that decision-making regarding AVR must also rely on the experience and judgment of the MDT. Although assessment tools help quantify risk, the question will remain as to what constitutes acceptable risk in an individual patient. Broad educational programs across the spectrum of clinicians involved in the care of AS patients are as important now as they were at the inception of the commercialization of TAVR. The rapid dissemination of TAVR, coupled with the significant declines seen in periprocedural complications and improvements in outcomes, can engender a false sense of security. For prohibitive and high-surgical risk AS patients, a group in which eligibility and appropriateness concerns remain, objective scrutiny leveraging observations of the nature reported here must be the standard of care. 
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